

Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019

<https://marketpublishers.com/r/A0643E5C4479EN.html>

Date: December 2019

Pages: 49

Price: US\$ 3,500.00 (Single User License)

ID: A0643E5C4479EN

Abstracts

Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019

SUMMARY

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Alpha-2C adrenergic receptor or ADRA2C is an alpha-2 adrenergic receptor. It mediates the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. This receptor plays a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system.

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 1 respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Schizophrenia, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Cognitive Disorders, Dementia Associated With Alzheimer's Disease, Depression, Generalized Anxiety Disorder (GAD), Major Depressive Disorder, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Pervasive Developmental Disorder (PDD), Post-Traumatic Stress Disorder (PTSD) and Psychiatric Disorders.

The latest report Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action

(MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C)

The report reviews Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Overview

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Companies Involved in Therapeutics Development

Avineuro Pharmaceuticals Inc

Bayer AG

Denovo Biopharma LLC

Otsuka Holdings Co Ltd

SK Biopharmaceuticals Co Ltd

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Drug Profiles

AVN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexpiprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexpiprazole LAI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DB-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fadaltran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-PSY - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Dormant Products

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Discontinued Products

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Product Development Milestones

Featured News & Press Releases

Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder

Feb 22, 2019: Health Canada approves Otsuka and Lundbeck's REXULTI (brexpiprazole) as Adjunctive treatment of Major Depressive Disorder

Feb 14, 2019: Lundbeck and Otsuka report phase III data evaluating Brexpiprazole for the treatment of manic episodes associated with bipolar I disorder

Dec 21, 2018: European launch of Rexulti (brexpiprazole) commences in Switzerland

Nov 30, 2018: Otsuka and Lundbeck report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)

Oct 29, 2018: Otsuka and Lundbeck report positive brexpiprazole results

Jul 31, 2018: Lundbeck and Otsuka's Rxulti (brexpiprazole) approved by the European Commission

Jun 01, 2018: Lundbeck and Otsuka's Rxulti (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults

May 24, 2018: Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease

Apr 18, 2018: REXULTI Tablets, a New Antipsychotic Drug, Launched in Japan

Jan 19, 2018: Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia

Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101

Nov 01, 2017: Lundbeck and Otsuka will initiate a third phase III trial to evaluate the use of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type

Oct 12, 2017: Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder

Sep 13, 2017: Otsuka and Lundbeck To Present Data On brexpiprazole at upcoming Psych Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Avineuro Pharmaceuticals Inc, H2 2019

Pipeline by Bayer AG, H2 2019

Pipeline by Denovo Biopharma LLC, H2 2019

Pipeline by Otsuka Holdings Co Ltd, H2 2019

Pipeline by SK Biopharmaceuticals Co Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

COMPANIES MENTIONED

Avineuro Pharmaceuticals Inc

Bayer AG

Denovo Biopharma LLC

Otsuka Holdings Co Ltd

SK Biopharmaceuticals Co Ltd

I would like to order

Product name: Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/A0643E5C4479EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0643E5C4479EN.html>